<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4664">
  <stage>Registered</stage>
  <submitdate>22/10/2014</submitdate>
  <approvaldate>22/10/2014</approvaldate>
  <nctid>NCT02273973</nctid>
  <trial_identification>
    <studytitle>A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)</studytitle>
    <scientifictitle>A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-positive/HER2-negative, Early Stage Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-000568-28</secondaryid>
    <secondaryid>GO28888</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Letrozole
Other interventions - Placebo
Treatment: drugs - Taselisib

Placebo Comparator: Letrozole + Placebo - Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.

Experimental: Letrozole + Taselisib - Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.


Treatment: drugs: Letrozole
Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.

Other interventions: Placebo
Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.

Treatment: drugs: Taselisib
Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With Objective Response (OR) by Centrally Assessed Breast Magnetic Resonance Imaging (MRI) via Modified Response Evaluation Criteria in Solid Tumors (mRECIST)</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants with Total Pathologic Complete Response (total pCR), Defined as Having pCR in Both Breast and Axilla, Using American Joint Committee on Cancer Staging System</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With OR by Centrally Assessed Breast MRI via mRECIST in PIK3CA Mutant (MT) Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With Total pCR, Defined as Having pCR in Both Breast and Axilla, Using American Joint Committee on Cancer Staging System in PIK3CA MT Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With OR by Centrally Assessed Breast MRI via mRECIST in PIK3CA Wildtype (WT) Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Total pCR Defined as Having pCR in Both Breast and Axilla, Using American Joint Committee on Cancer Staging System in PIK3CA WT Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With OR by Breast Ultrasound via mRECIST in PIK3CA MT Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With OR by Breast Ultrasound via mRECIST in PIK3CA WT Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With OR by Mammography via mRECIST in PIK3CA MT Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With OR by Mammography via mRECIST in PIK3CA WT Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With OR by Clinical Breast Exam (Palpation) via mRECIST in PIK3CA MT Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With OR by Clinical Breast Exam (Palpation) via mRECIST in PIK3CA WT Participants</outcome>
      <timepoint>From Baseline to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Central Assessments of Changes in Ki67 levels</outcome>
      <timepoint>From Baseline to Week 3 and Surgery (Weeks 17-18); and Week 3 to Surgery (Weeks 17-18)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preoperative Endocrine Prognostic Index (PEPI) Score</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Enhancing Tumor Volume as Measured by Breast MRI</outcome>
      <timepoint>From Baseline to Surgery (Weeks 17-18)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Score for Health-Related Quality of Life Measured by the European Organization for Research C30 (EORTC QLQ-C30)</outcome>
      <timepoint>Weeks 1, 5, 9, 13, 16, 4 week Post-Surgery (surgery will be performed on Weeks 17-18)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Score for Treatment of Cancer Quality of Life Questionnaire BR23 (QLQ-BR23)</outcome>
      <timepoint>Weeks 1, 5, 9, 13, 16, 4 week Post-Surgery (surgery will be performed on Weeks 17-18)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Adverse Events</outcome>
      <timepoint>Baseline up to 22 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female participants

          -  Postmenopausal status

          -  Histologically confirmed invasive breast carcinoma, with all of the following
             characteristics: (i) Primary tumor greater than or equal to (&gt;/=) 2 centimeters (cm)
             in largest diameter (cT1-3) by MRI; (ii) Stage I to operable Stage III breast cancer;
             (iii) Documented absence of distant metastases (M0)

          -  Estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative
             (HER2-) breast cancer

          -  Breast cancer eligible for primary surgery

          -  Tumor tissue from formalin-fixed paraffin-embedded cores (FFPE) core biopsy of breast
             primary tumor that is confirmed as evaluable for phosphatidylinositol-4,5-bisphosphate
             3-kinase, catalytic subunit alpha (PIK3CA) mutation status by central histopathology
             laboratory

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Fasting glucose less than or equal to (&lt;/=) 125 milligrams per deciliter (mg/dL)

          -  Adequate hematological, renal, and hepatic function

          -  Absence of any psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Ability and willingness to comply with study visits, treatment, testing, and to comply
             with the protocol, in the investigator's judgment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any prior treatment for primary invasive breast cancer

          -  Participants with cT4 or cN3 stage breast tumors

          -  Bilateral invasive, multicentric, or metastatic breast cancer

          -  Participants who have undergone excisional biopsy of primary tumor and/or axillary
             lymph nodes or sentinel lymph node biopsy

          -  Type 1 or 2 diabetes requiring antihyperglycemic medication

          -  Inability or unwillingness to swallow pills

          -  Malabsorption syndrome or other condition that would interfere with enteric absorption

          -  History of prior or currently active small or large intestine inflammation (such as
             Crohn's disease or ulcerative colitis). Any predisposition for gastrointestinal (GI)
             toxicity requires prior approval from the Medical Monitor.

          -  Congenital long QT syndrome or QT interval corrected using Fridericia's formula (QTcF)
             &gt;470 milliseconds (msec)

          -  Diffusing capacity of the lungs for carbon monoxide (DLCO) &lt;60% of the predicted
             values

          -  Clinically significant (i.e., active) cardiovascular disease, uncontrolled
             hypertension, unstable angina, history of myocardial infarction, cardiac failure class
             II-IV

          -  Any contraindication to MRI examination

          -  Active infection requiring intravenous antibiotics

          -  Participants requiring any daily supplemental oxygen

          -  Clinically significant history of liver disease, including viral or other known
             hepatitis, current alcohol abuse, or cirrhosis

          -  Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic
             dysfunction, physical examination finding, or clinical laboratory finding giving
             reasonable suspicion of a disease or condition that contraindicates the use of an
             investigational drug, that may affect the interpretation of the results, or renders
             the participants at high risk from treatment complications

          -  Significant traumatic injury within 3 weeks prior to initiation of study treatment

          -  Major surgical procedure within 4 weeks prior to initiation of study treatment

          -  Inability to comply with study and follow-up procedures

          -  History of other malignancy within 5 years prior to screening, except for
             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or
             Stage I uterine cancer</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>12/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>334</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>8/09/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Kinghorn Cancer Centre; St Vincents Hospital - Darlinghurst</hospital>
    <hospital>Newcastle Mater Misericordiae Hospital; Oncology - Waratah</hospital>
    <hospital>Victorian Breast and Oncology Care - East Melbourne</hospital>
    <hospital>Cabrini Medical Centre; Oncology - Malvern</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode> - East Melbourne</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>6150 - Murdoch</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>St. Veit/Glan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Namur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SC</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Vi単a del Mar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Pardubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Pribram</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>El Salvador</country>
      <state>Salvador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Cloud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-Les-Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bielefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gelsenkirchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>L端beck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>M端nster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Witten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Guatemala</country>
      <state>Guatemala City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Guatemala</country>
      <state>Guatemala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kecskemet</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Liguria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Chihuahua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Panama</country>
      <state>Panama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Otwock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coru単a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Caceres</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castellon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Girona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Jaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Lerida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Baden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Chur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Locarno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bournemouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Camberley</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>SOLTI Breast Cancer Research Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Breast International Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Austrian Breast and Colorectal Cancer Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a two-arm, randomized, double-blind, multicenter, pre-operative study to evaluate the
      effect of combining letrozole and GDC-0032 (also known as taselisib) versus letrozole and
      placebo in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth
      factor receptor 2 (HER2) untreated, Stage I-III operable breast cancer. Participants will be
      randomized into one of the two treatment arms with a 1:1 randomization ratio. Letrozole at
      2.5 milligrams (mg) will be dosed once daily plus either Taselisib at 4 mg (two 2-mg tablets)
      or placebo on a 5 days-on/ 2 days-off schedule for a total of 16 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02273973</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>